Review anchor
Casein kinase 2
PROTEIN FAMILY · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Casein kinase 2
CHEMBL3832943
PROTEIN FAMILY
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Casein kinase 2 as ChEMBL target CHEMBL3832943, mapped to UniProt P67870. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL3832943
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P67870
Casein kinase II subunit beta
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Casein kinase 2 matters
Casein kinase 2 is reviewed as Casein kinase II subunit beta (UniProt P67870); the current evidence base includes 1 approved drug, 355 compounds, and 123 assays, with lead potency reaching pChEMBL 10.1.
Protein context
Casein kinase II subunit beta
Casein kinase II subunit beta Sequence length is 215 aa.
Review this target as Casein kinase 2, mapped to UniProt P67870. ChEMBL maps the protein component as Casein kinase II subunit beta. Sequence length is 215 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P67870
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 1 approved drug, 355 compounds, and 123 assays for this target. The dominant activity type is IC50. CHEMBL5419810 is the current potency anchor at pChEMBL 10.1.
Use CHEMBL5419810 as the tractability anchor when discussing potency (pChEMBL 10.1).
Activity source · ChEMBL 36 via Core Engine
1 approved
pChEMBL 10.1
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Casein kinase 2 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P67870, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
355
Total Compounds
123
Total Assays
1
Approved Drugs
IC50: 207.0, KI: 28.0, EC50: 10.0, KD: 4.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL5419810
|
10.1 | Ki | — |
|
|
No preferred name
CHEMBL4848224
|
9.6 | IC50 | — |
|
|
No preferred name
CHEMBL1230165
|
9.4 | Ki | Clinical |
|
|
No preferred name
CHEMBL1682283
|
9.4 | Ki | — |
|
|
No preferred name
CHEMBL4846181
|
9.4 | Ki | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
MITOXANTRONE
CHEMBL58
|
1987 |
Source Header